The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Apparently a major announcement may be coming almost imminently: Valirx is to abandon its previous "dead-end" approach - which, incidentally, cost millions - in favour of a new far-reaching and hopefully cheaper strategy dubbed "Blue Horizon". The possibilities may be enormous, I gather.
First candidate is Camelot 1.
Methodology? You buy a small piece of paper and cross your fingers. A source claiming to be close to the company gushingly revealed: "The trick is getting just the righr combination of numbers."
Blue skies ahead.
https://www.bbc.co.uk/news/uk-scotland-scotland-business-21385418
They overreached themselves by spending a fortune on a state-of-the-art lab and a collagen firm. Hung out to dry, were swallowed (almost) whole by a customer.
"The Group will update the market on interim dividend payments with the half year results, following receipt of the update from the regulator and based on macroeconomic conditions at the time.
The Board remains committed to future capital returns. In 2021, the Board intends to accrue dividends and resume its progressive and sustainable ordinary dividend policy with the dividend at a higher level than 2020. As normal, the Board will give due consideration at year end to the size of the final dividend payment and any return of surplus capital in addition to the ordinary dividend, based on circumstances at the time."
My diary shows final ex-div. March 18th March and paid 23th April together with Q1 statement 5 days after that and paid 25th May.
My attention was grabbed by the huge pool of (our) funds held in CETI above the legal and bank's requirements. Presumably increasing profitability will increase the headroom to release that?
don't think so - that was Bown. Slater sold 1/2 holding for 50-66p (after covering his initial input). What - 2 and 1/2 million pounds profit? I never suggested any insider dealing. But the maths was obvious: if Slater thought Valirx would "BOOM" he wouldn't have sold, would he?